Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension (Q81147601)
Jump to navigation
Jump to search
scientific article published on 24 April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension |
scientific article published on 24 April 2008 |
Statements
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension (English)
Martin Busch
Sybille Franke
Gunter Wolf
Richard D Rohde
Günter Stein
Collaborative Study Group